DELBERT Laboratories Are Proud to Announce the Acquisition From Noventia Pharma Srl of the European Marketing Authorisation of CEPLENE® 0.5mg/0.5ml
DELBERT Laboratories are proud to announce the acquisition from Noventia Pharma Srl of the European MA of CEPLENE® 0.5mg/0.5ml, solution for injection (histamine dihydrochloride) on September 12, 2022, and strengthens its commitment in hematology-oncology in Europe.
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study published in Blood in 2006 and received orphan drug designation in 2005 1,2,3.
Acute myeloid leukemias are rare genetic diseases. In Europe, the incidence is estimated at 3.7/100,000 new cases per year. The prognosis for AML is unfavourable with a 5-year relative survival rate of 19%4.
DELBERT Laboratories (https://laboratoires-delbert.fr/) is a French pharmaceutical company specialized in the "renewal of essential medicines" frequently affected by marketing termination, stock shortages, particularly in times of crisis.
"We are focused on keeping essential medicines available to patients in 3 therapeutic areas (Antiinfectives, CNS and Oncology), with the mission of maintaining the therapeutic arsenal of doctors and preventing well-balanced patients from changing treatments.The acquisition of Ceplene's® MA in Europe is part of this strategy to maintain essential medicines and make available medicines with clinical benefit in rare diseases," said Eric Fidelin (Head of Strategy & Global Development).
With this acquisition, DELBERT Laboratories strengthens its presence in hematological oncology.
About DELBERT Laboratories
The mission of DELBERT Laboratories is to maintain access to Drugs of Major Therapeutic Interest for patients. Every year, Delbert Laboratories acquires new drugs whose future is compromised.
DELBERT Laboratories focuses its efforts on finding production sites in Europe. With their collaborators and the support of clinicians, galenicians, engineers and chemists, DELBERT Laboratories are reviving these drugs in order to guarantee their availability to the medical profession and patients.
DELBERT Laboratories will reach more than €30m in turnover in 2022 with double-digit growth each year and already markets 14 products (including 13 originators) with hospital or specialists reserved prescriptions.
DELBERT Laboratories financed this acquisition thanks to trusting relationships with their financial partners who strongly support these values focused on patient access to Drugs of Major Therapeutic Interest.
http://www.laboratoires-delbert.fr/
References:
1. Brune et al., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood, 1 july 2006 volume 108, number 1, 88-96
2. Nilsson, Malin S., et al. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology 188.4 (2020): e49
3. Ceplene® Epar, 2008 - EMEA/H/C/000796
4. Visser et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012 Nov;48(17):3257-66.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005760/en/
Contact information
Press Contact : G-Cliquet Consultant – contact@cliquet-consultant.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOGAS Mourns the Death of Their Beloved Chairman and Founder Vincent Louis Mogas3.5.2024 19:30:00 CEST | Press release
MOGAS mourns the death of their beloved chairman and founder Vincent Louis Mogas, who died on May 2, 2024 in Houston, Texas. Louis spent his life building a valve manufacturing business and a company culture that stood for goodness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240503919754/en/ V. Louis Mogas, Founder and Chairman of MOGAS Industries (1939 - 2024) (Photo: MOGAS Industries Inc.) MOGAS Industries was formed in May 1973 when Louis Mogas purchased a small machine shop in Houston. He soon acquired the rights to service and manufacture ball valves from Cameron Iron Works. Under Louis' leadership, the Company studied valve failures and established an R&D department that customized valves for specific applications. Since 2000, MOGAS has established sales and service offices in Australia, China, Europe, Canada, South America, Middle East and India. Early on, Louis Mogas introduced business behaviors that became the
Ververica Achieves ISO 27001 Certification, Bolstering Data Security3.5.2024 18:08:00 CEST | Press release
Ververica, a comprehensive streaming data platform provider, announces the achievement of ISO 27001 certification, a significant milestone in its commitment to data security and governance. This certification is internationally recognized as the gold standard for information security management systems (ISMS), and demonstrates the company’s commitment to protecting sensitive corporate and customer data against emerging cyber threats. For Ververica and its customers, this ensures that data is managed under the strictest security protocols, enhancing trust and confidence in Ververica’s ability to handle sensitive information securely and effectively. Ververica's security operations utilize Vanta, a trusted third-party management platform, for rigorous real-time monitoring and security alerts. To further enhance transparency and customer trust, Ververica has introduced a dedicated Trust Center webpage where stakeholders and potential customers can review live detailed information about se
Lone Star Announces Acquisition of ERIKS3.5.2024 15:07:00 CEST | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate has acquired ERIKS N.V., a specialized pan-European industrial components distributor and engineering service provider. Financial terms of the transaction were not disclosed. Founded in 1940, ERIKS has established itself as a European leader in specialized industrial services with over 200 locations in 12 countries. ERIKS’ deep industry experience, technical knowledge, local distribution network and dedicated engineering facilities allow it to develop advanced, customized solutions that drive performance improvements, deliver cost savings and add measurable technical and commercial value for its customers. Donald Quintin, Chief Executive Officer and Global President of Lone Star, said, "ERIKS represents an exciting investment opportunity and a valuable addition to our European investment portfolio. This acquisition aligns with our strategy of investing in market leading businesses that exhibit both growth and operating imp
Mars, Incorporated Enters Exclusive Discussions to Acquire the Entire Stake in French Veterinary Diagnostics Businesses Cerba Vet and ANTAGENE Held by the Cerba HealthCare Group3.5.2024 15:00:00 CEST | Press release
Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE. Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland. With approximately 140 Associates, Cerba Vet provides full animal-related service diagnostics with complete clinical and anatomic pathology testing as well as endocrinology, microbiology, serology, hematology, chemistry, and other advanced tests, to veterinary practitioners. Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually. Headquartered in Lyon, France, ANTAGENE is a leading player in animal genetics in Europe, recognised for its expertise in DNA testing for dogs, cats, horses and wildlife. ANTAGENE offers tests glo
Adtran and GLDS integrate Mosaic CP with BroadHub ® for enhanced broadband service billing and management3.5.2024 14:00:00 CEST | Press release
Adtran today announced that GLDS’s customer management and billing platform, BroadHub®, is now integrated with Adtran’s Mosaic CP and its SDX Series of optical line terminals (OLTs). Building on a longstanding partnership, the collaboration enhances automated service management by enabling instantaneous adjustments to network conditions and rapid responses to customer demands. It promises to boost service capabilities and operational efficiencies for service providers globally, offering advanced scalability for growing networks and real-time data analytics for improved service management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240503338277/en/ Adtran’s partnership with GLDS is helping service providers simplify customer management and streamline billing processes. (Photo: Business Wire) “Our strategic partnership with Adtran is driven by a shared commitment to empowering service providers with robust customer managem